



Antimicrobial activity and Cu(II) complexes of Schiff bases derived from ortho-aminophenol and salicylaldehyde derivatives

Abdullahi Owolabi Sobola^a and Gareth Mostyn Watkins^b

^aDepartment of Chemistry, Lagos state University, Ojo, Nigeria

^bDepartment of Chemistry, Rhodes University, Grahamstown, South Africa

ABSTRACT

A series of 2-hydroxy-phenylimino(methyl)phenol Schiff bases have been evaluated for their *in vitro* antibacterial and antifungal activity against *Escherichia coli* ATCC® 8739™*, *Staphylococcus aureus* subsp. *aureus* ATCC® 6538™*, *Bacillus subtilis* subsp. *spizizenii* ATCC® 6633™* and *Candida albicans* ATCC® 2091™*. The Schiff bases were obtained from the condensation of 2-aminophenol with salicylaldehyde, 2-hydroxy-3-methoxy benzaldehyde (*o*-vanillin) and 2-hydroxy-4-methoxybenzaldehyde (*p*-vanillin). The Schiff base ligands were characterized with elemental analysis, ¹H- and ¹³C-NMR, infrared and UV-Visible spectral data. The salicylaldehyde and the *o*-vanillin analogues possess significant activity against all the tested organisms. In addition, the Schiff bases coordinate to Cu(II) ions as dibasic tridentate ligands via the imine nitrogen and the deprotonated phenolic oxygen atoms. The complexes were of the form [CuL]; bridging through the phenolic oxygen atom to form binuclear Cu(II) complexes, [CuL]₂. All the complexes have high melting or decomposition temperature (> 250 °C) and were insoluble in common coordinating solvents. Thus, no antimicrobial activity was recorded for the complexes.

Keywords: Antimicrobial activity, ortho-amino phenol, salicylaldehyde, binuclear complexes

INTRODUCTION

Schiff bases have many applications in various fields of chemistry such as catalysis [1-4], electrochemistry [5-6], organic syntheses [7-9] and more importantly medicinal values. They are important intermediates in a number of enzymatic reactions involving interactions of the amino group of an enzyme with a carbonyl group of the substrate. Schiff bases have been reported to possess antimicrobial [10-14], antiviral [15], anticancer [16 - 19] and anti-inflammatory activity [20]. The imine functional group (HC=N) is believed to be responsible for the biological activity of Schiff base compounds. Several reports have indicated that Schiff bases with less or no activity became more potent upon chelation with metal ions [21-22]. Schiff bases are often used as ligands in coordination chemistry to form metal complexes [4-7, 9-13, 23-24] owing to their metal binding ability. Polydentate ligands such as N₂O₂, NNNN and ONO form stable complexes with metal ions due to the close proximity of the donor sites which afford a five- or six- member chelate rings. In this study, we present the evaluation of the antimicrobial activity of a series of ONO Schiff base ligands derived from condensation of *o*-aminophenol with benzaldehyde derivatives viz: 2-hydroxybenzaldehyde, 2-hydroxyl-3-methoxybenzaldehyde and 2-hydroxy-4-methoxy benzaldehyde. The synthesis and characterization of Cu(II) complexes of the Schiff base ligands is also presented.

EXPERIMENTAL SECTION

2.1. Chemicals and instrumentation

All the chemicals were of reagent grade (supplied by Sigma-Aldrich or Merck) and used as supplied.

The ^1H - and ^{13}C - NMR spectra were recorded in deuterated DMSO-*d*₆ with SiMe₄ as internal standard on Bruker Avance NMR equipment operating at 400 MHz. The mid-infrared absorption frequencies (4000-700 cm⁻¹) were recorded on a Perkin Elmer Spectrum 100 FT-IR equipped with universal attenuated total reflectance (ATR) accessory while the far-infrared (700-30 cm⁻¹) spectra were recorded in nujol mull on a Perkin Elmer Spectrum 400 FT-IR. The UV/Visible spectra were obtained from PerkinElmer Lambda 25 spectrophotometer. The elemental analysis, CHN, was done on Vario MICRO V1.6.2 elemental analysen systeme GmbH while the percentage metal content was determined on PerkinElmer A Analyst atomic absorption spectrometer. The melting points (uncorrected) of the compounds were determined using Galenkemp melting point apparatus. The micro-organisms were purchased from Microbiologics (Cape Town, South Africa).

2.2. Synthesis of the Schiff base ligands

The Schiff base ligands, L¹ - L³ (sal-2-phen; ovan-2-phen; and pvan-2-phen) were synthesized according to the general synthetic procedure in the literature [4-7] by condensing salicylaldehyde, *o*-vanillin and *p*-vanillin with 2-aminophenol respectively. The synthesized ligands are designated as sal-2-phen, ovan-2-phen, and pvan-2-phen, corresponding to ligands L¹ - L³.

2.2.1. Ligand L¹ (sal-2-phen)

1.07 mL (10.00 mmol) of salicylaldehyde was refluxed with 1.10 g (10.00 mmol) of 2-aminophenol in ethanol for 2 hr to obtain an orange solution. The solution was reduced under suction and an orange precipitate was obtained. The precipitate was filtered under suction, washed with ethanol and recrystallized from ethanol. It was dried over silical gel in a dessicator. Yield: 1.94 g (91%); δH (400 MHz, CDCl₃): 13.78(1H, s, Ar-OH); 9.77(1H, s, Ar-OH); 8.97(1H, s, HC=N); 7.62(1H, d); 7.36(2H, dd); 7.25(1H, t); 7.06(2H, t); 6.93(1H, t). δC (400 MHz, CDCl₃): 161.62(Ar-OH); 160.67(HC=N); 151.07(Ar-OH); 134.87(Ar-N=C); 132.78, 128.01, 119.54, 119.51, 119.44, 118.68, 116.63, 116.45(Ar-C); (Found: C, 73.01; H, 5.29; N, 6.44%. Cal. for C₁₃H₁₁NO: C, 73.23; H, 5.20; N, 6.57%).

2.2.2. Ligand L² (ovan-2-phen)

The procedure is the same as ligand L¹ using *o*-vanillin and 2-aminophenol. A red precipitate was obtained. Yield: 2.40 g (97%); δH (400 MHz, CDCl₃): 14.44(1H, s, Ar-OH); 9.79(1H, s, Ar-OH); 8.86(1H, s, HC=N); 7.46(1H, d); 7.36(1H, d); 7.18(1H, t); 6.92(2H, dd); 6.46(1H, d); 6.41(1H, t) and 3.80(3H, s, -OCH₃). δC (400 MHz, CDCl₃): 166.54(HC=N); 164.68(Ar-OCH₃); 160.73(Ar-OH); ; 151.32(Ar-OH); 134.76(Ar-N=C); 128.20, 120.49, 119.85, 117.23, 113.87, 107.40, 101.91(Ar-C) and 56.24(-OCH₃); (Found: C, 68.89; H, 5.43; N, 5.72%; Cal. for C₁₄H₁₃NO₂: C, 69.12; H, 5.39; N, 5.76%).

2.2.3. Ligand L³ (pvan-2-phen)

The procedure is the same as ligand L¹ using *p*-vanillin and 2-aminophenol. A yellow precipitate was obtained. Yield: 2.20 g (91%); δH (400 MHz, CDCl₃): 14.39(1H, s, Ar-OH); 8.84(1H, s, HC=N); 7.44(1H, d); 7.30(1H, d); 7.12(1H, t); 6.86(2H, dd); 6.45(1H, d); 6.40(1H, t) and 3.79(3H, s, -OCH₃). δC (400 MHz, CDCl₃): 162.36(HC=N); 152.12(Ar-OCH₃); 148.96(Ar-N=C); 147.37(Ar-OH); 133.01(Ar-Br); 128.27, 128.14, 124.30, 119.00, 115.44(Ar-C), 56.57(-OCH₃); (Found: C, 69.31; H, 5.45; N, 5.70%; Cal. for C₁₅H₁₅NO₂: C, 69.12; H, 5.39; N, 5.76%).

2.3. SYNTHESIS OF THE COMPLEXES

0.123 g (0.617 mmol) of copper acetate monohydrate, Cu(OAc)₂.H₂O, was dissolved in 10 mL ethanol and added drop-wisely to a vigorously stirring 0.30 g (1.23 mmol) ethanolic solution of ligand L¹. A green precipitate of the complex was obtained immediately. It was filtered under suction, washed thoroughly with ethanol and dried over silical gel in a desiccator. The same procedure was repeated for the other complexes. The physical and analytical data for the complexes are presented in table 1 below.

2.4. BIOLOGICAL STUDY

The Schiff base ligands and their respective Cu(II) complexes were screened for their in vitro antibacterial and antifungal activity against *Escherichia coli* ATCC® 8739™*, *Staphylococcus aureus subsp. aureus* ATCC® 6538™*, *Bacillus subtilis subsp. spizizenii* ATCC® 6633™* and *Candida albicans* ATCC® 2091™*.

2.4.1. DISC DIFFUSION TECHNIQUE

The qualitative antimicrobial susceptibility testing of the compounds was evaluated using the disc diffusion technique [21].

Each test organism was inoculated onto a nutrient agar plate and incubated at 37 °C for 24 hrs to obtain the primary culture. Several discrete colonies were picked from the culture to make a bacterial suspension (10 mL) in a test tube using saline water. The turbidity of the suspension was compared with 0.5 Mc Farland standard to obtain 10^6 - 10^8 CFUs. The bacterial suspension (0.1 mL) was inoculated onto Mueller Hinton plate and the sterile discs that have been impregnated with the test compounds were firmly placed on it. The assay was inoculated at 37 °C for 16 hrs and the zone of inhibition was measured as millimeters diameter. Ampicillin and dimethylformamide (DMF) were used as standard antibacterial drug and control solvent respectively. The test was repeated two more times for those compounds that showed activity of more than 6.5 mm and their activity was recorded as average zone of inhibition in table 3. Similar procedure was repeated for the antifungal susceptibility testing of the compounds using potato disc assay and ketoconazole in place of Mueller Hinton agar and penicillin respectively.

2.4.2. MINIMUM INHIBITORY CONCENTRATION (MIC)

The quantitative antimicrobial activity of the test compounds was evaluated using macro dilution broth method according to Clinical and Laboratory Standard Institute (formerly NCCLS) [21]. Two-fold serial dilutions of the compounds were prepared in 96 micro wells plates using sterile nutrient broth as diluent. The plates were inoculated with 5 μ L bacterial suspensions containing 10^6 - 10^8 CFUs and incubated at 37 °C for 16-18 hrs. The MIC value was defined as the lowest concentration of the compounds giving complete inhibition of visible growth. The MIC values for the compounds varied from 0.15625 mg/mL to 0.01221 mg/mL and the result is presented in table 4.

RESULTS AND DISCUSSION

The Schiff base ligands (L1 - L3) were prepared by condensing equimolar amount of 2-aminophenol with salicylaldehyde, o-vanillin and p-vanillin under reflux in absolute ethanol. The Cu(II) complexes were, however, synthesized using 1:2 molar ratio of the Schiff base ligands and the Cu(II) ions using copper(II) acetate monohydrate.

Table1: Physical and analytical data for the complexes

Complexes	Colour	% Yield	M.Pt	Molar mass	%Found (Calculated)				Λ_M ($\Omega^{-1} \text{cm}^2 \text{mol}^{-1}$)
					C	H	N	Cu	
[CuL ¹] ₂	Green	93	>250	274.78	56.01 (56.82)	3.11 (3.30)	4.93 (5.10)	23.5 (23.13)	*ns
[CuL ²] ₂	Green	60	>250	304.81	54.98 (55.17)	3.39 (3.64)	4.55 (4.60)	20.95 (20.85)	*ns
[CuL ³] ₂	Green	85	>250	304.81	54.98 (55.17)	3.37 (3.64)	4.60 (4.60)	20.70 (20.85)	*ns


N.B.: *ns = not soluble

Table 2: Infrared and UV-Visible spectral data for the ligands and the complexes

Compound	V_{OH} (cm^{-1})	V_{C-H} (cm^{-1})	$V_{C=N}$ (cm^{-1})	$V_{C=O}$ (cm^{-1})	V_{Cu-N} (cm^{-1})	V_{Cu-O} (cm^{-1})	λ (nm)
L ¹	3134 - 1949	3043	1626	1272, 1304	-----	-----	275, 334, 444
[CuL ¹] ₂	-----	3058	1613	1341, 1379	540	489	409, 676
L ²	3129 - 1952	3056	1626	1277, 1306	-----	-----	280, 350, 450
[CuL ²] ₂	-----	-----	1610	1355, 1317	535	472	435, 628
L ³	3158 - 2043	2971	1624	1276, 1286	-----	-----	337, 421
[CuL ³] ₂	-----	3058	1599	1357, 1304	555	475	421, 641

3.1. ELEMENTAL ANALYSIS RESULT

The microanalysis results for the ligands tallied with the expected values, thus confirming the purity of the compounds. In addition, the values for the complexes (table 1) indicated a 1 : 1 ratio for the copper ion and the Schiff base ligand. Thus, the complexes were of the form [CuL], which must thus dimerize [22], to form a neutral four-coordinate Cu(II) complexes, [CuL]₂. The dimerization is presumed to occur from bridging between the two Cu(II) centres via the deprotonated phenolic oxygen atoms as shown in figure 1. The molar conductance of the complexes could not be determined because of its non-solubility in common solvent, including DMSO. The insolubility of the Cu(II) complexes in common coordinating solvent together with high melting or decomposition temperature (greater than 250 °C) has been used to support the dimeric nature of the complexes [22].



L^1 : R = H; R' = H; L^2 : R = OMe; R' = H; L^3 : R = H; R' = OMe


Figure 1: Proposed structure for the complexes

3.2. NMR STUDIES

The NMR spectral data for the ligands are presented in the experimental section. The Schiff base ligands exist in enol form; as indicated by the non-splitting of the methine proton (figure 2) and the appearance of the phenolic protons [23 - 25]. The phenolic hydroxyl proton in the aldehyde moiety of the ligands absorbed downfield as a broad singlet at 14.44 - 13.77 ppm; while the broad signal at 9.79 - 9.77 ppm was attributable to the hydroxyl proton of the ortho-aminophenol moiety. The broadness of the signals was due to a strong hydrogen bonding between the imine N and the hydroxyl protons. On the other hand, the azomethine proton, HC=N, appeared as a strong singlet at 8.97 - 8.85 ppm, which was corroborated by the ^{13}C -NMR signal at 166.54 - 160.73 ppm. The purity of the ligands was indicated by the disappearance of the aldehyde and the amino protons; CHO (δ = 9 - 10 ppm) and NH₂ (δ = 3 - 4 ppm); in the ligands spectra. All the aromatic protons were accounted for and absorbed at 6.50 - 7.50 ppm. Lastly, the signals at 3.80 ppm and 56.55 - 56.24 ppm (^{13}C -NMR), correspond to the methoxyl protons of ligands L^2 and L^3 resulting from *o*-vanillin and *p*-vanillin respectively.

3.3. INFRARED STUDY

The infrared spectral data for the ligands are presented in table 2. The mid-infrared spectra of the ligands exhibit a broad absorption band at 3134 - 1949 cm^{-1} , corresponding to the hydroxyl protons of the Schiff base ligands. The broadness and the low frequency values indicate the existence of a strong intra-molecular hydrogen bonding between the O-H and the N-H groups [26 - 27]. This band, however, disappeared in the spectra of the complexes due to deprotonation and involvement of the oxygen atom in the coordination sphere. In addition, the phenolic C-O stretching vibration bands at 1277 - 1272 cm^{-1} and 1306 cm^{-1} - 1286 cm^{-1} were blue-shifted to 1341 - 1301 cm^{-1} and 1375 - 1355 cm^{-1} respectively, confirming the complexation via the phenolic oxygen atoms [28 - 30]. Likewise, the strong band at 1626 - 1624 cm^{-1} is attributed to the imine (C=N) functional group of the free ligands. The band red-shifted, to 1613 - 1599 cm^{-1} , in the complexes, indicating coordination through the imine nitrogen [29 - 30]. The ligands are therefore considered bidentate. The mode of coordination of the ligands was further substantiated by the appearance of two new bands at 555 - 535 cm^{-1} and 489 - 472 cm^{-1} ; in the far-infrared spectra of the complexes. These bands are assigned to $\nu_{\text{Cu-N}}$ and $\nu_{\text{Cu-O}}$ respectively [10, 29]. The discussion so far, thus suggest that the Schiff bases (L^1 - L^3) coordinate as dibasic tridentate ligands.

Figure 2: $^1\text{H-NMR}$ spectrum for ligand L^2

3.4. UV/VISIBLE STUDIES

The electronic transition study of the free ligands was carried out in methanol. Three distinct bands were observed at 280 - 275 nm; 350 - 334 nm and 450 - 421 nm. The first two bands correspond to the $\pi \rightarrow \pi^*$ and $n \rightarrow \pi^*$ transitions of the azomethine chromophore [31 - 32] respectively. The absorption band at above 400 nm (450 - 421 nm) has been previously assigned to the keto-imine form of ortho - hydroxylsalicylaldehydes in polar and non-polar solvents [31]. The tautomerism is thought to occur via an intramolecular (or intermolecular in protonic solvents) hydrogen transfer to the imine nitrogen.




Figure 3: Electronic spectra for the Cu(II) complexes

In addition, the solid reflectance spectra of the complexes exhibit a single broad band (figure 3) typical of a distorted copper (II) system, at 676 - 628 nm. The band is attributable to the ${}^2A_{1g} - {}^2B_{1g}$ transition characteristic of Cu(II) ion in a square planar geometry [33]. The shift of the absorption band to lower energy than expected for square planar geometry at 568 nm for square planar N,N'-ethylenebis(salicylideneimine) Copper(II) [34], may be due to the distortion of the square planar geometry towards tetrahedral [33]. The square planar geometry is achieved by the coordination of the Schiff base ligands (L1 - L3) as ONO dibasic tridentate via the imine N, and the deprotonated phenolic oxygen atoms with consequent bridging via one of the enolic oxygen as shown in figure 1.

3.5 ANTIMICROBIAL RESULTS

The diameter of zone of inhibition and the MIC results for the Schiff bases are presented in tables 3 and 4 respectively. Ligands L¹ and L² are significantly active against all the tested microorganisms as shown in figure 4; with L² being specifically more potent than the standard antifungal drug, ketoconazole. L³ is only active against *Bacillus subtilis subsp. spizizenii*, a non-pathogenic gram-positive bacteria, and *Candida albicans*. The least inhibition of microbial growth was observed with the *Escherichia coli*, possibly due to the presence of an outer protective layer called lipopolysaccharide. The outer layer provides additional fortification to the cell membrane; limiting the concentration of test compound streaming through the bacterial cell wall. Thus, gram negative bacteria are more resistant to antibiotic treatment compared to the gram positive bacteria as evident in this study.

Table 3: Diameter of zone of inhibition (mm) for the Schiff base ligands (L¹ - L³)

	Gram Positive		Gram negative	Fungus
	<i>S. aureus</i>	<i>B. Substilis</i>	<i>E. coli</i>	<i>C. albicans</i>
L ¹	28	28	12	08
[CuL ¹] ₂	*ns	*ns	*ns	*ns
L ²	25	21	14	25
[CuL ²] ₂	*ns	*ns	*ns	*ns
L ³	-	11	-	07
[CuL ³] ₂	*ns	*ns	*ns	*ns
DMF (control)	-	-	-	-
Ampicillin (antibacterial)	52	38	28	
Ketoconazole (antifungal)				20

*ns: Not soluble

Figure 4: MIC values (1 x 10⁻¹ mg/mL) for the Schiff base ligands [L¹ - L³]

Compounds	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>
L1	3.9063	0.1221	3.9063
L2	0.4883	0.1221	0.9766
L3	-	15.625	-




Figure 4: Antimicrobial activity of the Schiff base ligands [L¹ - L³]

Chelation enhances the antimicrobial activity of free ligands as this reduces the polarity of the metal ions and consequently increases the lipophilicity of the free ligands. However, all the complexes are not soluble in DMSO nor DMF and thus their biological activity could not be evaluated.

CONCLUSION

The salicylaldehyde and the *o*-vanillin analogues of the free Schiff base ligands exhibit significant antimicrobial activity against the tested organisms. The *p*-vanillin derivative is virtually non-active. All the Schiff base compounds form chelates with Cu(II) ions as dibasic tridentate ligands (ONO) via the enolic oxygen atoms and the imine nitrogen. In addition, bridging through the enolic oxygen suggests a binuclear four-coordinate Cu(II) complexes.

Acknowledgements

We are grateful to the Department of Chemistry, Rhodes University South Africa, for providing the facilities for this study.

REFERENCES

- [1] VB Sharma; SL Jain; B Sain, *J. Mol. Catal. A: Chem.*, **2004**, 219(1), 61-64.
- [2] RM Wang; CJ Hao; YP Wang; SB Li, *J. Mol. Catal. A: Chem.*, **1999**, 147(1-2), 173-178.
- [3] DI Carlo; M Mathew; K-K Gabriele; DJ Matthew; LJ Andrew, *Eur. J. Inorg. Chem.*, **2013** (9), 1541-1554.
- [4] S Bhunora; J Mugo; A Bhaw-Luximon; S Mapolie; J Van Wyk; J Darkwa; E Nordlander, *Appl. Organometal. Chem.*, **2011**, 25, 133-145.
- [5] S Ershad; L Sagathforoush; G Karim-nezhad; S Kangari, *Int. J. Electrochem. Sci.*, **2009**, 4(6), 846-854.
- [6] PE Martínez; BN Martínez; CR de Barbarín, *Adv. Technol. Mater. Mater. Process. J.* **2006**, 8(1), 41-48.
- [7] H. Tanaka; H. Dhimane; H. Fujita; Y. Ikemoto; S. Torii, *Tetrahedron Lett.*, **1988**, 29 (31), 3811-3814.
- [8] MJ Brown, *Heterocycles*, **1989**, 29(11), 2225-2244.
- [9] IIMathews; H Manohar, *Polyhedron*, **1991**, 10(23-24), 2851-28513.
- [10] V Reddy; N Patil; SD Angadi, *E- J. Chem.*, **2008**, 5(3), 577-583.
- [11] A Valent; M Melnik; D Hudecova; B Dudova; R Kivekas; MR Sundberg, *Inorg. Chim. Acta*, **2002**, 340, 15-20.
- [12] B Samanta; J Chakraborty; CR Choudhury; SK Dey; DK Dey; SR Batten; P Jensen; GPA Yap; S Mitra, *Struct. Chem.*, **2007**, 18, 33-41.
- [13] AE Şabik; M Karabörk; G Ceyhan; M; Tümer; M. Diğrak, *Int. J. Inorg. Chem.*, **2012**, 2012, 11 pages.
- [14] UI Singh; RKB Singh; WR Devi; CB Singh, *J. Chem. Pharm. Res.*, **2012**, 4(2), 1130-1135.
- [15] SP Singh; SK; Shukla; LP Awasthi, *Current Science*, **1983**, 52(16), 766-769.
- [16] MP Sathisha; VK Revankar; KSR Pai, *Metal-Based Drugs*, **2008**, 2008, 11 pages.
- [17] M Coluccia; A Nassi; A Boccarelli; D Giordano; N Cardellicchio; D Locker; M Leng; M Sivo, FP Intini; G Natile, *J. Inorg. Biochem.*, **1999**, 77(1-2), 31-35.
- [18] MM Kandeel; SM Ali; EKA Abed ElALL; MA Abdelgawad; PF Lamie, *J. Chem. Pharm. Res.*, **2012**, 4(9), 4097- 4106.
- [19] F Arjmand; F Sayeed; M Muddassir, *J. Photochem. and Photobiol. B: Biology*, **2001**, 103, 166-179.
- [20] S Bawa; S Kumar, *Indian J. Chem. Sect. B: Org. Chem. Incl. Med. Chem.*, **2009**, 48B(1), 142-145.
- [21] EA Elzahany; KH Hegab; SKH Khalil; NS Youssef, *Aust J. Basic and Appl. Sci.*, **2008**, **2(2)**, 210-220.
- [22] MS Islam; MA Farooque; MAK Bodruddoza; MA Mosaddik; MS Alam, *Online J. Biol. Sc.*, **2001**, 1(8), 711-713.
- [23] KT Joshi; AM Pancholi; KS Pandya; AS Thakar, *J. Chem. Pharm. Res.*, **2011** 3(4), 741-749.
- [24] R Vijayaganthila; A Nirmala; CH Swanthy, *J. Chem. Pharm. Res.*, **2011** 3(3), 635-638.
- [25] A Wanger; in: R Schwalbe; L Steele-Moore; AC Goodwin (Eds.). *Antimicrobial Susceptibility Testing Protocols*, Taylor and Francis group, London, **2007**; 6.
- [26] A Syamal; KS Kale, *Transition Met. Chem.*, **1979**, 4, 298-300.
- [27] GO Dudek; RH Holm, *J. Am. Chem. Soc.*, **1961**, 83, 3914.
- [28] G Yeap; S Ha; N Ishizawa; K Suda; P Boey; MW Kamil, *J. Mol. Struct.*, **2003**, 658(1-2), 87-99.
- [29] M Yildiz; Z Kilic; T Hokelek, *J. Mol. Struct.*, **1998**, 441(1), 1-10.
- [30] GC Percy; DA Thornton, *J. Inorg. Nucl. Chem.*, **1973**, 35, 2319-2327.
- [31] AW Baker; AT Shulgin, *J. Am. Chem. Soc.*, **1959**, 81, 1523-1529.
- [32] K Rathore; RKR Singh; HB Singh, *E-J. Chem.*, **2010**, 7(S1), S566-S572.
- [33] SA Abdel-Latif; HB Hassib; YM Issa, *Spectrochim. Acta Part A*, **2007**, 67, 950-957.

- [34] JE Kovacic, *Spectrochim. Acta*, **1967**, 23A, 183-187.
[35] Y Zhou; X Ye; F Xin; X Xin, *Transition Met. Chem.*, **1999**, 24, 118-120.
[36] R Ramesh; S Maheswaran, *J. Inorg. Biochem.*, **2003**, 96, 457-462.
[37] NH Al-Shaalan, *Molecules*, **2011**, 16, 8629-8645)
[38] F Lloret; M Mollar; J Faus; M Julve; I Castro, *Inorg. Chim. Acta*, **1991**, 189(2), 195 - 206.